Trending in Rare Diseases: PYRUKYND Approval, Venglustat Review and more

This edition highlights major developments across the rare disease landscape, including European Commission approval of PYRUKYND for thalassemia, FDA priority review for venglustat in type 3 Gaucher disease, encouraging Lynozyfic data in AL amyloidosis, and a subgroup signal from the CARES study of anselamimab. Additional updates include a Tavneos label revision in Japan, Elfabrio approval in Korea for Fabry disease, discussion around ALS regulatory pathways, and a licensing agreement expanding development of civorebrutinib for rare kidney diseases.

Видео Trending in Rare Diseases: PYRUKYND Approval, Venglustat Review and more канала LucidQuest